Cutaneous T-cell lymphoma associated with the acquired immunodeficiency syndrome

Nahass, G. T.

doi:10.1001/archderm.127.7.1020

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9][10][11]22 HIV-infected patients with CTCL differ from nonHIV infected patients by immunophenotyping: CD8ϩ cells, as seen in our patients, predominate in the dermal infiltrates, although CD4ϩ predominant CTCL have also been reported in HIV infected patients. 8,9,11 Patients in our study were identified retrospectively, therefore sera were not available for HTLV-1 testing. In previous reports, sera from four patients with HIV-associated atypical cutaneous lymphoproliferative disorder were negative for antibodies to HTLV-1 by ELISA.…”

Section: Increased Decreasedmentioning

confidence: 84%

“…1,2 Well characterized dermatologic conditions which may present with pruritus in these patients include scabies, papular pruritic eruption of human immunodeficiency virus (HIV), eosinophilic pustular folliculitis, drug reactions, and, less commonly, cutaneous T cell lymphoma (CTCL). [3][4][5][6][7][8][9][10][11] Other less well defined pruritic disorders have been described including recent reports of an atypical cutaneous lymphoproliferative disorder (ACLD) which mimics histologically CTCL. [12][13][14][15][16][17] In 1989, Longacre et al and Janier et al first described this disorder in two patients with acquired immunodeficiency syndrome (AIDS).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Atypical cutaneous lymphoproliferative disorder in patients with HIV infection

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Increased Decreasedmentioning

confidence: 84%

mentioning

confidence: 99%

Atypical cutaneous lymphoproliferative disorder in patients with HIV infection

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Multiple cases of MF have now been reported in immunosuppressed patients because of organ transplantation or human immunodeficiency virus infection [42]. …”

Section: Risk Factorsmentioning

confidence: 99%

Mycosis fungoides: Review of Epidemiological Observations

Suárez-Varela¹,

González²,

Vila

et al. 2000

Dermatology

View full text Add to dashboard Cite

Background: Mycosis fungoides (MF) is a chronic cutaneous T-cell lymphoma characterized by small cells with cerebriform nuclei that usually express a mature peripheral T-helper cell (CD4+) immunophenotype. Its evolution is typically quite slow, with years between the first manifestations and development of advanced stages of disease. Objective: The purpose of the present paper is to contribute to the material about MF already present in the literature. The review articles that have appeared to date fundamentally address the morphological characteristics, diagnostic criteria and treatment of the disease; in contrast, the present study centers on the evolution of the incidence of MF and on the knowledge of the possible risk factors implicated in its development. Methods: Review of published papers about MF epidemiology. Results: The evidence suggests that the incidence is increasing, but this may be artifactual due to improved diagnostic techniques. The risk of MF is limited to gender and race, being higher in males and in blacks. Survival is highly stage dependent, but 90% of patients survive 15 years with only 10% of cutaneous involvement. Few risk factors have been identified, but several studies have found an association with industrial exposure, particularly to oils. Conclusion: MF is a rare disease and its risk factors have not been studied in any great detail. A European case-control study in progress will substantially increase the evidence available and progress towards identifying a prevention strategy.

show abstract

“…An epidermotropic CD81 lymphoproliferative disease has been observed in HIV infected individuals with severe CD-4 lymphopenia [5,[15][16][17][18]. When tested, some of these patients have also been infected with HTLV-2, but the majority had a polyclonal rather than a monoclonal CD81 Tcell lymphoproliferative process.…”

Section: Discussionmentioning

confidence: 99%

CD8+ cutaneous T‐cell lymphoma successfully treated with bexarotene: A case report and review of the literature

et al. 2008

View full text Add to dashboard Cite

CD81 cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD41 CTL and there have been no reports about its use in CD81 CTCL. Herein, we report on a patient whose CD81 CTCL completely responded to treatment with bexarotene. Am. J. Hematol. 83:744-746, 2008. V

show abstract

Cutaneous T-cell lymphoma associated with the acquired immunodeficiency syndrome

Cited by 10 publications

References 0 publications

Atypical cutaneous lymphoproliferative disorder in patients with HIV infection

Atypical cutaneous lymphoproliferative disorder in patients with HIV infection

Mycosis fungoides: Review of Epidemiological Observations

CD8+ cutaneous T‐cell lymphoma successfully treated with bexarotene: A case report and review of the literature

Contact Info

Product

Resources

About